Product ID |
Product Name |
CAS# |
Purity |
Y3310372 |
1-(2,2-Dichloroethenyl)-1H-1,2,3-benzotriazole |
681446-85-5 |
99% |
Y3308838 |
N-Cyclohexyl-3-{[2-(cyclohexylcarbamoyl)-ethyl]disulfanyl}propanamide |
2935-88-8 |
95% |
Y3311661 |
3H,4H,5H-Benzo[e]indazole |
305860-76-8 |
94% |
Y3310265 |
1-[1-(1H-Pyrazol-1-yl)cyclohexyl]-1H-1,2,3-benzotriazole |
478239-75-7 |
95% |
Y3309521 |
1-[2-(1H-1,2,3-Benzotriazol-1-yl)pent-4-en-2-yl]-1 1,2,3-benzotriazole |
851429-84-0 |
95% |
Y3310532 |
5-Acetyl-2-ethoxybenzaldehyde |
99865-31-3 |
99% |
Y3309726 |
1-[(3-Benzoyl-8-methylindolizin-2-yl)methyl]-1H-1,2,3-benzotriazole |
305862-05-9 |
TECH |
Y3310205 |
N3,N6-bis(2-bromophenyl)pyridazine-3,6-diamine |
302933-19-3 |
98% |
Y3162151 |
4-(2-Thienyl)piperidine Hydrochloride |
630116-60-8 |
95% |
Y3308835 |
Ethyl (2Z)-2-benzyl-3-hydroxy-5-phenylpent-2-en-4-ynoate |
776297-02-0 |
95% |
Y3308377 |
5-Amino-3-pyridin-4-ylpentan-1-ol |
26684-80-0 |
95% |
Y3306001 |
1-[2-Phenyl-1-(pyridin-2-yl)ethyl]-1H-1,2,3-benzotriazole |
159493-97-7 |
98% |
Y3306997 |
2-(1H-1,2,3-Benzotriazol-1-yl)-3-methoxy-1,1-diphenylprop-2-en-1-ol |
865075-77-0 |
97% |
Y3308108 |
1-[(2-Methoxyphenyl)(4-methylphenyl)methyl]-1H-1,2,3-benzotriazole |
303756-46-9 |
98% |
Y3170341 |
N-[(2-Cyanophenyl)methyl]-N-ethylmethanesulfonamide |
1378325-89-3 |
95% |
Y3309678 |
3-Iodo-4-propoxybenzaldehyde |
2743031-56-1 |
98% |
Y3311138 |
3-Fluorophenyl trifluoroacetate |
2376621-45-1 |
98% |
Y3293425 |
Orexin 2 Receptor Agonist 2 |
2114324-60-4 |
98% |
Y3292709 |
PB2 |
914940-24-2 |
99% |
Y3288065 |
Enhanced Green Fluorescent Protein (EGFP) (200-208) |
323198-39-6 |
98% |
Y3312530 |
Dentonin |
400090-20-2 |
98.63% |
Y3309943 |
USP30 inhibitor 11 |
2067332-64-1 |
99.81% |
Y3162123 |
4-(3-Pyridinyl)benzenemethanamine dihydrochloride |
2490432-24-9 |
95% |
Y3288660 |
Biotin-PEG3-aldehyde |
889443-90-7 |
95% |
Y3294348 |
mTOR inhibitor-8 |
2489196-70-3 |
98% |
Y3167340 |
PROTAC PD-1/PD-L1 degrader-1 |
2447066-37-5 |
98% |
Y3164370 |
RAC-(1R,3R,5R)-3-AMINOBICYCLO[3.1.0]HEXANE-1-CARBOXYLIC ACID HYDROCHLORIDE |
2307733-71-5 |
93% |
Y3314654 |
4-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-2,6-dimethoxyphenol hydrochloride |
2771189-66-1 |
95% |
Y3290210 |
ENPP1 Inhibitor 43 |
2631703-41-6 |
99% |
Y3288456 |
Bliretrigine |
1233229-75-8 |
99% |
Y3290571 |
SRI-37240 |
883956-47-6 |
99% |
Y3163605 |
Zastaprazan |
2133852-18-1 |
99% |
Y3163483 |
(R)-Olacaftor |
1899111-41-1 |
98% |
Y3296442 |
Cetirizine Impurity C dihydrochloride |
2702511-37-1 |
99% |
Y3309882 |
PW0464 |
1643462-93-4 |
97% |
Y3161918 |
Aß/tau aggregation-IN-1 |
2252162-81-3 |
95% |
Y3162303 |
Ocarocoxib |
215122-22-8 |
99.94% |
Y3114865 |
NT1-O14B |
2739805-64-0 |
98% |
Y3288929 |
Sonlicromanol hydrochloride |
2162149-24-6 |
99% |
Y3161919 |
(R)-IL-17 modulator 4 |
2446804-29-9 |
99.57% |
Y3289230 |
PROTAC STING Degrader-1 |
2762552-74-7 |
98% |
Y3296795 |
Zaloglanstat |
1513852-12-4 |
99% |
Y3286239 |
SN-008 |
2249106-01-0 |
98% |
Y3169196 |
Cyclic-di-GMP diammonium |
609343-82-0 |
99.72% |
Y3162307 |
TLR7 agonist 4 |
2413016-42-7 |
98% |
Y3161886 |
CCG258747 |
2615910-00-2 |
99% |
Y3292389 |
Ar-V7-IN-1 |
2230880-25-6 |
99% |
Y3297011 |
ZW4864 free base |
2632259-92-6 |
99% |
Y3162122 |
YSK05 |
1318793-78-0 |
98.0% |
Y3286463 |
Upacicalcet sodium |
2052969-18-1 |
98% |
Y3163724 |
avß5 integrin-IN-1 |
2615912-33-7 |
99.72% |
Y3163725 |
EP2 receptor antagonist-1 |
848920-08-1 |
99% |
Y3163623 |
CXCR2 antagonist 2 |
2647464-91-1 |
99.12% |
Y3163727 |
Treprostinil palmitil |
1706528-83-7 |
99.56% |
Y3294962 |
SAR247799 |
1315311-14-8 |
97% |
Y3311693 |
Tasipimidine sulfate |
1465908-73-9 |
99% |
Y3163728 |
KRAS G12C inhibitor 28 |
2649004-88-4 |
99% |
Y3161910 |
Usmarapride |
1428862-33-2 |
98% |
Y3162032 |
VU6028418 |
2649803-05-2 |
99.52% |
Y3290130 |
Elinzanetant |
929046-33-3 |
95%+ |
Y3162034 |
ONO-0300302 |
856689-51-5 |
99.43% |
Y3292888 |
(R)-Elsubrutinib |
1643570-23-3 |
98% |
Y3289606 |
Rho-Kinase-IN-2 |
2573071-18-6 |
99% |
Y3291104 |
RAD51-IN-5 |
2690367-19-0 |
98% |
Y3290854 |
PERK-IN-5 |
2616821-91-9 |
99% |
Y3288856 |
KIF18A-IN-1 |
2600559-12-2 |
98% |
Y3285982 |
VPC-70619 |
2361742-30-3 |
99% |
Y3162221 |
FNC-TP |
2457357-99-0 |
95.0% |
Y3162222 |
ARX-1796 |
2245880-46-8 |
99.66% |
Y3163416 |
AMPK-IN-3 |
2417674-27-0 |
98.51% |
Y3292918 |
FD223 |
2050524-24-6 |
98% |
Y3163550 |
(32-Carbonyl)-RMC-5552 |
2382768-55-8 |
95.04% |
Y3289692 |
MS170 |
2376136-61-5 |
99% |
Y3290097 |
CDK7/12-IN-1 |
2654075-94-0 |
99% |
Y3163418 |
SARS-CoV-2-IN-7 |
2570461-66-2 |
99% |
Y3164431 |
BTX161 |
2052301-24-1 |
98.58% |
Y3169166 |
USP15-IN-1 |
2260826-16-0 |
99.42% |
Y3287011 |
LDC4297 hydrochloride |
2319747-14-1 |
98% |
Y3294631 |
ALV1 |
2438124-79-7 |
95% |
Y3313828 |
CDK4/6-IN-11 |
2139329-47-6 |
96% |
Y3163855 |
GFB-12811 |
2775311-17-4 |
98.00% |
Y3163711 |
FGFR-IN-1 |
1513860-41-7 |
99.35% |
Y3292033 |
FGFR2-IN-2 |
2677709-81-6 |
98% |
Y3161902 |
UniPR129 |
1639159-47-9 |
99% |
Y3161903 |
MMI-0100 |
1039342-24-9 |
99.55% |
Y3160635 |
HPK1-IN-8 |
1214561-09-7 |
98.56% |
Y3288629 |
ERK1/2 inhibitor 7 |
2648455-13-2 |
98% |
Y3287348 |
IDO/TDO-IN-1 |
2033173-01-0 |
99% |
Y3163730 |
ROC-0929 |
1048660-43-0 |
99.48% |
Y3289817 |
Glucokinase activator 3 |
1001417-92-0 |
98% |
Y3169179 |
(R)-Irsenontrine |
1429509-81-8 |
99.00% |
Y3162302 |
PDE10-IN-5 |
898562-99-7 |
97% |
Y3295327 |
IDO1-IN-19 |
2328099-11-0 |
98% |
Y3162300 |
Methyl 5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylate Hydrochloride |
1361381-55-6 |
91% |
Y3309017 |
2-(2,6-Dichlorophenoxy)acetamide |
722456-97-5 |
98% |
Y3311157 |
1,4,5-Triphenylpyrrolidin-2-one |
253429-95-7 |
95% |
Y3308919 |
(S)-1-(Trifluoromethyl)ethylisocyanate |
2409104-90-9 |
98% |
Y3304695 |
1-[(Pyridin-4-yloxy)methyl]-1H-1,2,3-benzotriazole |
301344-61-6 |
95% |
Y3311676 |
1-tert-Butyl-4-iodocyclohexane, mixture of isomers |
85592-89-8 |
90% |
Y3304944 |
phenyl(thiophen-3-yl)methanol |
102871-39-6 |
tech |